The following project, SMiPAX4, conducted in the academic group of Jean-Philippe Herbeuval (Univeristy of Paris, France), is at the cross section of immunology and pharmacology. Moreover, due to its direct application potential an...
ver más
¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video
Proyectos interesantes
SAF2017-82940-R
IDENTIFICACION DE LOS FACTORES QUE AFECTAN EL AGRUPAMIENTO Y...
254K€
Cerrado
BFU2011-30097
ESTUDIO DE LOS MECANISMOS MOLECULARES QUE REGULAN LOS PROCES...
47K€
Cerrado
NTasePro
NTase Products and Cyclic Nucleotide Signalling
2M€
Cerrado
CRITICS
Towards targeting chemokine receptors CCR7 and CCRL1 to cont...
210K€
Cerrado
SAF2009-07857
PAPEL DE LA QUIMIOQUINAS EN INFECCIONES VIRALES
380K€
Cerrado
PID2020-114147RB-I00
MODULACION DE LAS FUNCIONES DE LAS CELULAS DENDRITICAS MADUR...
121K€
Cerrado
Información proyecto SMiPAX4
Duración del proyecto: 32 meses
Fecha Inicio: 2022-06-09
Fecha Fin: 2025-02-28
Líder del proyecto
UNIVERSITE PARIS CITE
No se ha especificado una descripción o un objeto social para esta compañía.
TRL
4-5
Presupuesto del proyecto
245K€
Fecha límite de participación
Sin fecha límite de participación.
Descripción del proyecto
The following project, SMiPAX4, conducted in the academic group of Jean-Philippe Herbeuval (Univeristy of Paris, France), is at the cross section of immunology and pharmacology. Moreover, due to its direct application potential and the subsequent industrial placement at Ermium Therapeutics it is also cross sectional between academia and industry.
The main objective of the project is to understand the mode of action of small molecules, functionally causing a reduction of immune response, binding into the minor binding pocket of the G protein coupled receptor CXCR4. The signalling cascade as well as the implication of different expression levels of the target CXCR4 will be explored through different biochemical techniques and finalised by the establishing of a medium to high-throughput screening assay. Protein-protein interactions will be identified using Bioluminescence energy transfer (BRET) techniques, increase or decrease of second messenger molecules will be identified using biosensors, and phosphorylation states, up- or downregulation of (signalling) proteins will be measured using flow cytometry or western blotting. Inflammation of cells when controlling the impact of silencing certain signalling molecules will be controlled by measuring the levels of inflammation markers.
Due to the projects implication in (auto)immune and other inflammation diseases it is relevant for cluster 1, Health, of the Horizon Europe programme. The project shows great potential in the area of impact due to its unique target potentially helping people that do not respond well to already approved medication. Both, the dissemination of results producing multiple publications in peer reviewed journals, talks and posters at scientific meetings as well as the potential of creating market within the EU are very probable with completion of this project.